| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | tofacitinib | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 2 | Restasis | FAERS: 4 | US FAERS | |
| 3 | Dexamethasone | FAERS: 2 | US FAERS | |
| 4 | Erlotinib Hydrochloride | FAERS: 2 | US FAERS | |
| 5 | Everolimus | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 6 | Imiquimod | FAERS: 2 | US FAERS | |
| 7 | Lenalidomide | FAERS: 2 | US FAERS | |
| 8 | Mitomycin | FAERS: 2 | US FAERS | |
| 9 | Moxifloxacin | FAERS: 2 | US FAERS | |
| 10 | lifitegrast | FAERS: 2 | US FAERS | |
| 11 | Azithromycin | FAERS: 1 | US FAERS | |
| 12 | Bimatoprost | FAERS: 1 | US FAERS | |
| 13 | Bortezomib | FAERS: 1 | US FAERS | |
| 14 | Cabozantinib S-malate | FAERS: 1 | US FAERS | |
| 15 | Fentanyl | FAERS: 1 | US FAERS | |
| 16 | Fingolimod Hydrochloride | FAERS: 1 | US FAERS | |
| 17 | Fluticasone | FAERS: 1 | US FAERS | |
| 18 | Insulin Glargine | FAERS: 1 | US FAERS | |
| 19 | Insulin | FAERS: 1 | US FAERS | |
| 20 | Lamotrigine | FAERS: 1 | US FAERS | |
| 21 | Nevirapine | FAERS: 1 | US FAERS | |
| 22 | Oxcarbazepine | FAERS: 1 | US FAERS | |
| 23 | Penicillamine | FAERS: 1 | US FAERS | |
| 24 | Sertraline | FAERS: 1 | US FAERS | |
| 25 | Sunitinib | FAERS: 1 | US FAERS | |
| 26 | Trifluridine | FAERS: 1 | US FAERS | |
| 27 | Triumeq | FAERS: 1 | US FAERS | |
| 28 | Warfarin | FAERS: 1 | US FAERS | |
| 29 | Zoledronic Acid | FAERS: 1 | US FAERS | |
| 30 | besifloxacin | FAERS: 1 | US FAERS | |
| 31 | bromfenac | FAERS: 1 | US FAERS | |
| 32 | dabrafenib | FAERS: 1 | US FAERS | |
| 33 | etonogestrel | FAERS: 1 | US FAERS | |
| 34 | gemcitabine | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 35 | mirabegron | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.